in 4 mL bottle NDC 0065-0002-03
Storage: Store at 2 - 25°C (36 - 77°F).
17 PATIENT COUNSELING INFORMATION
17.1 Slow or Delayed Healing
Patients should be informed of the possibility that slow or delayed healing may occur while using nonsteroidal anti-inflammatory drugs (NSAIDs).
17.2 Avoiding Contamination of the Product
Patients should be instructed to avoid allowing the tip of the dispensing container to contact the eye or surrounding structures because this could cause the tip to become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.
17.3 Contact Lens Wear
NEVANAC® should not be administered while wearing contact lens.
17.4 Intercurrent Ocular Conditions
Patients should be advised that if they develop an intercurrent ocular condition (e.g., trauma, or infection) or have ocular surgery, they should immediately seek their physician's advice concerning the continued use of the multi-dose container.
17.5 Concomitant Topical Ocular Therapy
If more than one topical ophthalmic medication is being used, the medicines must be administered at least 5 minutes apart.
17.6 Shake Well Before Use
Patients should be advised to shake the bottle well.
U.S. Patent No; 5,475,034
ALCON®
ALCON LABORATORIES, INC.
Fort Worth, Texas 76134 USA
© 2007 Alcon, Inc.
Nevanac (nepafenac)
PRODUCT INFO
Product Code 0065-0002 Dosage Form SUSPENSION
Route Of Administration OPHTHALMIC DEA Schedule
INGREDIENTS
Name (Active Moiety) Type Strength
nepafenac (nepafenac) Active 1 MILLIGRAM In 1 MILLILITER
mannitol Inactive
carbomer 974P Inactive
sodium chloride Inactive
tyloxapol Inactive
edetate disodium Inactive
benzalkonium chloride Inactive
sodium hydroxide Inactive
hydrochloric acid Inactive
water Inactive
IMPRINT INFORMATION
Characteristic Appearance Characteristic Appearance
Color Score
Shape Symbol
Imprint Code Coating
Size
PACKAGING
# NDC Package Description Multilevel Packaging
1 0065-0002-03 3 MILLILITER In 1 BOTTLE, PLASTIC None
Revised: 05/2008 ALCON LABORATORIES, INC.
|
